Chinese Academy of Sciences

Green Valley (shanghai) Pharmaceuticals Co., Ltd.

Shanghai Haihe Pharmaceutical Co., Ltd.

Other

Shanghai Fochon Pharmaceutical Co., Ltd.

China Petroleum & Chemical Corporation

Dalian University of Technology

Adir Et Compagnie

East China University of Science and Technology

Shanghai Research Institute of Petrochemical Technology, Sinopec

East China Normal University

Shanghai Green Valley Pharmaceutical Co., Ltd.

Cisen Pharmaceutical Co., Ltd.

Chongqing Fochon Pharmaceutical Co., Ltd.

Jinan University

Jian Ding

Meiyu Geng

Yi Chen

Zhenqing Zhang

Zehong Miao

Ao Zhang

Xianliang Xin

Jing Ai

Xia Peng

Qing Qi

Linghua Meng

Zhongping Xiao

Zilan Song

Fajun Nan

Chunhao Yang

Cun Tan

Hua Xie

Xiaoguang Du

Min Huang

Jia Tao Li

Weibo Wang

Lei Jiang

Xingdong Zhao

Yangming Zhang

Ling Chen

Jianhua Cao

Xiajuan Huan

Lei Li

Qiong Zhang

Yubo Zhou

Haohan Tan

Jianping Zuo

Xiang Wang

Weipeng Zhang

Mingbo Su

Hongbin Liu

Qiang Tian

Li Xing

Pierre Renard

Yang Liu

Wei Zhang

Yan Chen

Gang Liu

Jing Li

Wei Lu

Xin Wang

Lei Liu

Hong Iris Zhu

Ghanem Atassi

Fei Chen

Fan Zhang

Jingkang Shen

Xi Zhang

Ke Ding

Dejin Kong

Xin Xie

Xianlong Wang

Meng Wang

Ying Li

Zuwen Zhou

Rui Tan

Yanxin Liu

Tongshuang Li

Jing Sun

Lihua Jiang

Anhui Gao

Tao Meng

Zhengchao Tu

Qihong Liu

Yufang Xu

Yue Rong

Lanping Ma

Qiangang Zheng

Lijun Yang

Xuhong Qian

Huaying Li

Deqin Yang

Youhong Hu

Min Gu

Xiaoyun Lu

Li Linghu

Xiaomei Ren

Huixin Wan

Li Tan

Yan Zhang

Bing Xiong

Wei Lv

Xun Huang

Yong Gan

Yinchun Ji

Qian He

Ru Ling Zhou

Min Hou

Dong Xiao

Jiapeng Li

Zhang Zhang

Yanhong Chen

Shanshan Song

Qingyun Jiang

The present invention relates to a pyrimido[5,4-b]pyrrolizin compound represented by general formula I, an optical isomer thereof, a preparation method therefor, a pharmaceutical composition containing same, and a use thereof. The compound according to the present invention has good inhibitory activity on the kinase BTK at both the molecular level and the cellular level. Meanwhile, the compound also has good anti-tumor activity and pharmacokinetic properties in vivo.

Pyrimido[5,4-b]pyrrolizin compound, optical isomer thereof, preparation method therefor and use thereof

A fluorine-containing substituted benzothiophene compound and a pharmaceutical composition and an application thereof are described. The compound has the structure as shown in formula (I), in which the definitions of each group and substituent are as described in the description. A preparation method of the compound and an anti-tumor application thereof are also described.

Fluorine-containing substituted benzothiophene compound, and pharmaceutical composition and application thereof

The present invention relates to a mannuronic diacid oligosaccharide composition, comprising a mannuronic diacid of Formula (III) or a pharmaceutically acceptable salt thereof, wherein n is an integer from 1 to 9, m is 0, 1 or 2, and m′ is 0 or 1, and wherein the total weight of mannuronic diacids wherein n=1-5 is 80-95% of the total weight of the composition, and the ratio of the total weight of mannuronic diacids wherein n=1-3 to the total weight of mannuronic diacids wherein n=4-7 is between 1.0 and 3.5.

Composition of mannuronic diacid

The present application provides use of an algal proteoglycan extract and a composition comprising the same in treating or preventing tumor, pain, inflammation or diseases mediated by inflammatory factors.

Composition comprising an algal proteoglycan extract and use thereof

Provided in the present invention are a substituted amino six-membered nitric heterocyclic ring compound and a preparation and use thereof. In particular, provided in the present invention is a compound as shown by general formula (I) below, wherein the definition of each group is as described in the description. The compound of the present invention has an excellent tyrosine kinase inhibitory activity, and can thus be used to prepare a series of medicines for treating diseases related to tyrosine kinase inhibitory activity.

Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof

The invention provides an indolizine compound represented by formula I or a pharmaceutically acceptable salt thereof, a preparation method and a use thereof. The indolizine compound has an inhibitory effect on wild-type and/or mutant EZH2 or EZH1, and is expected to be developed into a novel drug for anti-tumor or for the treatment of autoimmune diseases. 

Indolizine compounds, preparation method and use thereof

The present invention relates to an alginic oligosaccharic diacid composition comprising a mannuronic diacid of Formula (IV) or a pharmaceutically acceptable salt thereof, wherein n is an integer selected from 1 to 9, m is selected from 0, 1 or 2, m' is selected from 0 or 1, and wherein the total weight of alginic oligosaccharic diacid wherein n=1-5 accounts for more than 60% of the total weight of the composition; the total weight of guluronic acids accounts for less than 50% of the total weight of the composition. 

Composition of alginic oligosaccharic diacids

The invention relates to a compound of formula (I): wherein variables are as defined in the specification. The compound is an inhibitor of an ERK kinase, e.g. ERK1 and/or ERK2 kinase. The invention also relates to the use of the compound and a method for preparing the compound, and a pharmaceutical composition containing the compound.

Compound having ERK kinase inhibitory activity and use thereof

The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of Parkinson's disease.

Use of mannuronic diacid composition in treatment of Parkinson's disease

The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of diabetes.

Use of mannuronic diacid composition in treatment of diabetes

The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of inflammation.

Use of mannuronic diacid composition in treatment of inflammation

The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of pain.

Use of mannuronic diacid composition in treatment of pain

The present invention relates to the application of mannuronic diacid oligosaccharide composition in the treatment of vascular dementia.

Use of mannuronic diacid composition in treatment of vascular dementia

Growing community of inventors

Shanghai, China

Jian Ding